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Background: Clear cell renal cell carcinoma (ccRCC) accounts for more than 80% of the cases of renal cell
carcinoma. In ccRCC deactivation of Von-Hippel-Lindau (VHL) gene contributes to the constitutive expression of
hypoxia inducible factors 1 and 2 alpha (HIF-α), transcriptional regulators of several genes involved in tumor
angiogenesis, glycolysis and drug resistance. We have demonstrated inhibition of HIF-1α by Se-
Methylselenocysteine (MSC) via stabilization of prolyl hydroxylases 2 and 3 (PHDs) and a significant therapeutic
synergy when combined with chemotherapy. This study was initiated to investigate the expression of PHDs, HIF-α,
and VEGF-A in selected solid cancers, the mechanism of HIF-α inhibition by MSC, and to document antitumor
activity of MSC against human ccRCC xenografts.
Methods: Tissue microarrays of primary human cancer specimens (ccRCC, head & neck and colon) were utilized to
determine the incidence of PHD2/3, HIF-α, and VEGF-A by immunohistochemical methods. To investigate the
mechanism(s) of HIF-α inhibition by MSC, VHL mutated ccRCC cells RC2 (HIF-1α positive), 786–0 (HIF-2α positive)
and VHL wild type head & neck cancer cells FaDu (HIF-1α) were utilized. PHD2 and VHL gene specific siRNA
knockdown and inhibitors of PHD2 and proteasome were used to determine their role in the degradation of HIF-1α
by MSC.
Results: We have demonstrated that ccRCC cells express low incidence of PHD2 (32%), undetectable PHD3, high
incidence of HIF-α (92%), and low incidence of VEGF-A compared to head & neck and colon cancers. This
laboratory was the first to identify MSC as a highly effective inhibitor of constitutively expressed HIF-α in ccRCC
tumors. MSC did not inhibit HIF-1α protein synthesis, but facilitated its degradation. The use of gene knockdown
and specific inhibitors confirmed that the inhibition of HIF-1α was PHD2 and proteasome dependent and VHL
independent. The effects of MSC treatment on HIF-α were associated with significant antitumor activity against
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http://www.biomedcentral.com/1471-2407/12/293Conclusions: Our results show the role of PHD2/3 in stable expression of HIF-α in human ccRCC. Furthermore, HIF-1α
degradation by MSC is achieved through PHD2 dependent and VHL independent pathway which is unique for HIF-α
regulation. These data provide the basis for combining MSC with currently used agents for ccRCC.
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Kidney cancer is associated with several gene mutations
including Von-Hippel-Lindau (VHL), fumarate hydratase
(FH) and succinate dehydrogenase (SDH) [1] and
accounts for 3% of all cancers with 2% of the total can-
cer deaths in the U.S [2]. Among all kidney cancers,
clear cell renal cell carcinoma (ccRCC) is the most com-
mon with a molecularly distinct phenotype [3] and con-
tain up to 91% nonfunctional VHL mutations [1] which
may leads to the constitutive expression of hypoxia in-
ducible factors 1 and 2 alpha (HIF-α). HIF-α are tran-
scription factors that regulate several genes (>100)
involved in angiogenesis, cell proliferation, apoptosis,
glycolysis, iron metabolism, drug resistance and other
cellular processes to adapt to low oxygen hypoxic condi-
tions in various solid tumors [4]. HIF-α are susceptible
to oxygen dependent degradation under regular oxyge-
nated conditions through the hydroxylation of proline
molecules by prolyl hydroxylases (PHDs). There are four
isoforms of PHDs (PHD1- 4) whose functions are differ-
ent in various cellular systems [5,6]. Under regular oxy-
gen conditions, HIF-1α is hydroxylated at proline 402
and proline 564 molecules by prolyl hydroxylases 2 and
3 (PHD2/3) which is then recognized by VHL and fur-
ther degraded by proteasome [7,8]. In general, PHD2
and PHD3 are expressed normally under normoxic con-
ditions and their hydroxylation activity is inhibited under
hypoxic conditions, resulting in the stable expression of
HIF-α proteins [9]. The preferential hydroxylation of
HIF-1α by PHD2 and HIF-2α by PHD3 has been
reported [7]. Recent report, however, indicates that
PHD2 and 3 hydroxylate HIF-1α and HIF-2α with simi-
lar efficiency [10]. The differences in cellular localization
of PHD 2 and 3 have been reported, showing that PHD2
expression mostly in cytoplasm and PHD3 in cytoplasm
and nucleus [11]. Recently, PHD3 mRNA deregulation
has been reported in several cancers including renal,
prostate, breast and melanoma [12]. PHD3 is not only
involved in the hydroxylation of HIF-α, but also has a
role in apoptosis [13,14].
Stable expression of HIF-α is regulated by synthesis
and degradation pathways. It is likely that a lower level
of HIF-α degradation pathway exists in ccRCC due to
mutations in VHL. Several modulators of PHD activity
have been implicated in HIF-stability. These include
enhanced levels of reactive oxygen species (ROS) [15],nitric oxide [16,17], 2-oxoglutarate, Fe (II), ascorbate, fu-
marate and succinate [15]. Recent report by Finely et al.,
showed that decreased levels of SIRT 3, mitochondrial
NAD-dependent deacetylase, resulted in increased cellu-
lar accumulation of ROS that contributes for the stability
of HIF-α [18].
To date, significant advancement in treatment of
ccRCC with VEGF targeted inhibitors, has provided a
proof of principle that targeting HIF-α, an upstream
regulator of VEGF, may result in significant therapeutic
benefits [1,19,20]. As an alternative to the development
of HIF-α targeting agents, the approach to develop
agents that promote the degradation of HIF-α through
activation of PHDs may be more productive in alleviat-
ing HIF-α signaling pathways [10]. Since the PHDs are
upstream regulators of HIF-α and their role in the deg-
radation of HIF-α in ccRCC expressing mutant VHL has
not been well investigated.
Selenium is an essential element extensively utilized in
prevention clinical trials, but has thus far produced con-
flicting results [21] . It is likely that effectiveness of sel-
enium is influenced by the selenium dose and types.
While selenomethionine (SLM) is extensively utilized in
prevention trials, Se-Methylselenocysteine (MSC) is
under development and offers biological and pharmaco-
logical properties not common with SLM. Our labora-
tory was the first to report that optimal dose and
schedule of MSC as highly effective inhibitor of ROS
[22], nitric oxide [23], and HIF-1α [22,23]. This inhib-
ition was associated with anti-angiogenic effect and
tumor vasculature maturation [24] leading to moderate
antitumor (30%) effect. Furthermore, remarkable thera-
peutic synergy was achieved in human tumor xenografts
when optimal dose and schedule of MSC was used in se-
quential combination with anticancer drugs [22,25]. We
have proved HIF-1α as a critical target molecule for MSC
effects demonstrating therapeutic synergy in HIF-1α
knockdown xenograft tumors with anticancer agent alone
as comparable to MSC combination with anticancer agent
[22]. HIF-1α inhibition by siRNA also sensitized hypoxic
human tumor cells to radiotherapy [26].
The current study was designed to a) investigate the
incidence of PHD2/3, HIF-α in selected human solid
cancers b) test the hypothesis that degradation of HIF-α
by MSC is PHD2 and proteasome dependent, VHL and
PHD3 independent and c) determine if these effects will
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De-identified human primary tumors of ccRCC, head &
neck, and colon cancers separately arranged in Tissue
microarrays (TMAs) (cores 6 mm in diameter)) and
available frozen tissues of ccRCC tumors with their
matched normal kidney were obtained from the Data
Bank and BioRepository (DBBR) core facility, Depart-
ment of Pathology, Roswell Park Cancer Institute,
according to the institutional review board (IRB)
approved protocols.
Chemicals and antibodies
Se-Methylselenocysteine (MSC) was obtained from
Sigma-Aldrich (St. Louis, MO). Methylselenic acid
(MSA), the active metabolite of MSC, was purchased
from PharmaSe Inc., (Lubbock, TX). L-[35 S]-Methionine
purchased from PerkinElmer (Waltham MA). HIF-1α
antibody was procured from R & D Systems (Minneap-
olis, MN) and Novus Biologicals (Littleton, CO). HIF-2α
antibody was purchased from Abcam (Cambridge, MA)
and Novus Biologicals (Littleton, CO). PHD 2 antibody
as procured from Novus Biologicals (Littleton, CO) and
PHD3 was obtained from Abcam (Cambridge, MA).
Proteasome inhibitor MG132 was purchased from Cal-
biochem (La Jolla, CA). Protein synthesis inhibitor cyclo-
heximide (CHX) was purchased from Sigma (St. Louis,
MO). Prolyl hydroxylases inhibitor dimethyloxaloyl gly-
cine (DMOG) was obtained from Frontier Scientific Inc.,
(Logan, UT).
Immunohistochemical methods
Human primary tumors and some normal tissues (10%
neutral buffered formalin fixed and paraffin embedded)
arranged in TMAs (core size 0.6 mm in diameter) of
ccRCC (number 88), head & neck (number 210) and colo-
rectal (number 65) were used to evaluate expression of
HIF-1α and PHD2 and 3 simultaneously in ccRCC and
separately for the individual markers in head & neck and
colorectal cancers by the immunohistochemical method
developed previously by our laboratory [27]. Briefly, paraf-
fin sections (5 μm thickness) were cut from TMA blocks
and immunostained with automatic immunostainer for
HIF-1α, PHD2 and PHD3. This is a well characterized,
validated, and reliable immunohistochemical method util-
izing a Catalyzed Signal Amplification (CAS) reagent that
made HIF-1α nucleus confined detection possible. HIF-2α
was detected with the same method using anti-HIF-2α
from Novus Biologicals (Littleton, CO) at a concentration
of 0.5 μg/ml. Vascular endothelial growth factor-A
(VEGF-A) was immunostained according to the methoddescribed by us [22] as single staining. Well known posi-
tive, negative and isotype controls were included in all
immunohistochemical studies. All immunohistochemical
slides were reviewed by a board certified, experienced
pathologist (K.T).
Semiquantitative assessment of the immunostainings
HIF-1α and HIF-2α immunostainings were considered
specific if they were localized in the nuclei, while for
PHD2 and PHD3 cytoplasmic staining were considered
as specific. Staining intensity was categorized as: not de-
tectable in any tumor cells or the specific staining in the
majority of tumor cells was weak (w), moderate (m) or
strong (s). Staining intensity in the cores were compared
with the known strong positive controls and categorized
accordingly. Since one core (0.6 mm in diameter) of the
TMA contains roughly 600 tumor cells (varies based on
the size of stroma, necrosis, inflammatory cell infiltra-
tion, size of vessels etc.) the estimated 1% of the total
tumor cell population (in general 5–6 tumor cells at
least) was considered as positive. During the original
reading of the TMA’s the staining in the cores was esti-
mated and categorized with a letter (w, m, s) indicating
the staining intensity and with a number which showed
the distribution of the percentage of tumor cells stained
positively like: s/100 meaning 100% of the tumor cell
stained strongly for the marker. The raw data were tabu-
lated, and based on that we have provided additional
data to the result section in order to better characterize
the overall staining.
Cell culture and MSA treatment
Clear cell renal cell carcinoma cells RC2 which express
HIF-1α only and 786–0 cells which express HIF-2α [28]
were utilized for the studies. RC2 cells were cultured in
DMEM with glucose, 10% FBS, 1.0% PSN. 786–0 cells
were cultured in RPMI-1640 with 10% FBS and 1% PSN.
Head & Neck cancer cells FaDu were purchased from
American Type Culture Collection (Manassas, VA) and
cultured in RPMI-1640 supplemented with 10% FBS.
Cells were regularly tested for Mycoplasma. Since the
HIF-1α was not expressing constitutively in FaDu cells,
0.5% oxygen hypoxic conditions were used with a hyp-
oxia chamber (IN VIVO 400 Ruskinn Technology Ltd.,
Cincinnati, OH) to induce HIF-1α as described earlier
[22]. Cells were seeded in the tissue culture plates and
allowed to grow to a confluence of ~70%, then treated
with MSA at a dose of 1 μM for FaDu, 10 μM for RC2
and 8–10 μM for 786–0 and incubated for 8–24 h. Un-
treated controls were maintained for comparison.
Effect of MSA on cell growth
Cells (400–600) were seeded in 96 well plates, allowed to
grow overnight, and treated with various concentrations (3,
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maintained without treatment. Cells were washed with
medium for 3 times to remove MSA, fresh medium was
added and incubated at 37 °C incubator for 96 h. Growth
inhibition of cells was determined by sulforhodamine-B
(SRB) assay as described previously [22]. Briefly, medium
was taken out and cells were fixed with 10% trichloroacetic
acid and left the plates at 4 °C for at least 2 hours. Plates
were processed for washing and staining with SRB using
automated plate washer. The unbound SRB stain was
removed by washing and the stain bound to the cells was
measured using plate reader (Bio Tek Instruments, model
EL340, Winooski, VT) at 570 nm. Percent growth inhib-
ition was determined considering growth of untreated con-
trol cells as 100%.
Effect of MSA on HIF-1α protein synthesis and
degradation
To determine the MSA effect on HIF-1α protein synthe-
sis, FaDu cells were treated with known protein synthe-
sis inhibitor cycloheximide (CHX) alone and in
combination with MSA for 1–24 h under 0.5% hypoxic
conditions because HIF-1α degradation was observed
after 18-24 h of MSA exposure in these cells. To investi-
gate the half-life of HIF-1α, RC2 cells were treated with
CHX for 2, 4 and 8 h time points and evaluated HIF-1α
inhibition in these cells. Further studies to evaluate the
effect of MSA on HIF-1α protein synthesis, RC2 cells
were treated with CHX with and without MSA for 8 h
because at this earliest time point we found pronounced
HIF-1α inhibition by MSA in RC2 cells. Total protein
extracts were isolated and determined the HIF-1α ex-
pression by western blot. To further determine MSA
effects on total protein synthesis, RC2 cells were pulsed
with 35 S-methionine for 1 h before the 5 h incubation
with 10 μM MSA or 5 μM CHX as described [29]. Total
protein extracts (20 μg) were used to determine the
incorporated radiolabeled methionine by SDS polyacryl-
amide gel electrophoresis followed by autoradiography.
Gel was stained with coomassie blue stain and showed
as loading control.
Total 35 S-methionine incorporated in the proteins was
also determined by counting the radioactivity present in
the protein extracts using Beckman LS 6000 Scintillation
Counter. Total number of counts was calculated in one
milligram of protein and compared with untreated con-
trols. To investigate the effect of MSA on proteasome
mediated degradation of HIF-1α, FaDu cells were treated
with MSA and proteasome inhibitor N-[(phenylmethoxy)
carbonyl]-L-leucyl-N-[(1 S)-1-formyl-3-methylbutyl]-L-
leucinamide, (MG132) alone and in combination, and
the HIF-1α protein level was determined by western
blot analysis. The effect of MG132 on the degrad-
ation of HIF-1α in RC2 cells was determined bytreating cells with MSA and MG132 alone and in combin-
ation concurrently and pretreatment of MG132 1 h before
treating with MSA for 8 h. Protein extracts were prepared
from the cells and used for determining HIF-1α expres-
sion by western blot.
PHDs inhibition by dimethyloxallyl glycine (DMOG)
PHDs activity inhibitor, DMOG was used to treat cells
with and without MSA to determine the HIF-1α degrad-
ation effects of MSA. FaDu which do not express HIF-1α
under normoxic culture conditions were treated separately
with 0.5 mM DMOG alone and in combination with MSA
for 18–24 h. Cells were processed for extraction of protein
and western blot was performed to measure the HIF-1α
levels. Similarly, RC2 cells which express HIF-1α constitu-
tively were treated with 0.5 mM DMOG and 10 μM MSA
alone and in combination and determined the HIF-1α
levels in these cells.
SiRNA transfection
To determine the PHD2 role in the degradation of HIF-
1α by MSA, RC2 cells expressing PHD2 were utilized to
knockdown PHD2. To evaluate whether MSA is utilizing
VHL independent pathway of degradation of HIF-1α,
FaDu cells which express wild type VHL were used to
knockdown VHL by siRNA. Since RC2 cells express
mutated VHL we have used FaDu cells for VHL knock-
down experiments. Validated Silencer sure siRNA for
the egg-laying-defective nine 1 (EGLN1) gene for PHD2
protein was purchased from Ambion/Invitrogen (Carls-
bad, CA). VHL SMART pool siRNA was purchased
from Thermo Scientific (Lafayette, CO). Cells were
allowed to grow overnight to reach ~70-80% confluence
and siRNA transfection was performed using a Lipofec-
tamine 2000 transfection reagent as per the procedure
described by the manufacturer (Invitrogen, Carlsbad,
CA). Briefly 200-500nM of siRNA was used with Lipo-
fectamine 2000 and transfected into the cells and incu-
bated at 37 °C, 5% CO2 for 24 h. Cells were trypsinized
and seeded onto new tissue culture dishes and allowed
to grow for 24–48 h. Cells were treated with and with-
out MSA for 18–24 h and processed for the extraction
of protein to determine the VHL, PHD2 and HIF-1α
levels by western blot. Each experiment was repeated at
least twice.
Western blot analysis
Western blot analysis was performed to determine the
effect of MSA or MSC on HIF-α, and PHDs as per the
procedure described previously [22]. Briefly, after the
treatments, cells were washed twice with PBS, scrapped
with a cell scrapper, centrifuged and cell pellets were
collected. Protein extracts were prepared from the cell
pellets using the lysis buffer with protease inhibitors and
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tumor tissues were collected, and snap-frozen in liquid
nitrogen. Protein extracts were prepared by homogeniz-
ing with a Polytron homogenizer in lysis buffer. Twenty
to forty μg of protein was used to separate on high effi-
cient Mini-Protean precast 4-20% gradient gel (Bio-Rad)
and transfer to the PVDF membrane. Primary antibodies
for HIF-1α (R and D systems 1:250/500 dilution), HIF-2α
(Abcam, 1:250/500 dilution) PHD2 (Novus Biologicals
1:5000 dilution), PHD3 (Abcam 1:500 dilution), and VHL
(Cell Signaling 1:500 dilution) were used and incubated
for 1 h at room temperature or overnight at 4 °C. Respect-
ive HRP conjugated secondary antibodies were used and
incubated for 1 h. Proteins were detected using Lumi-
Light PLUS western blotting kit (Roche, Indianapolis, IN)
for HIF-1α, PHD2/3 and VHL and an ECL advance kit for
HIF-2α.
Vascular endothelial growth factor (VEGF) analysis by
enzyme-linked immunosorbent assay (ELISA)
RC2 and 786–0 cells were seeded in 6 well plates and
allowed to grow overnight in a regular culture medium.
The cell culture medium was aspirated and fresh
medium was added with reduced serum (1% FBS) and
treated with MSA for 24 h. Cell culture supernatants
from untreated and MSA treated cells were collected,
centrifuged and immediately used for measuring
secreted VEGF using a Quantikine Human VEGF Im-
munoassay kit as per the manufacturer’s instructions (R
& D Systems, Minneapolis, MN). Briefly, 50 μl of Assay
Diluent was added to each well. Plate layout was marked
with standard, control and experiment and 200 μl of
VEGF standard, cell culture supernatants of control and
experiment were added and incubated for 2 h at room
temperature. Each well was aspirated and washed 3
times with wash buffer and 200 μl of VEGF conjugate
was added and incubated for 2 h at room temperature.
Aspiration and washing was repeated 3 times and 200 μl
substrate solution was added to each well, the plate was
protected from light and incubated for 20 min at room
temperature. Reaction was stopped by adding 50 μl stop
solution and mixing the plate gently, optical density was
recorded at 450 nm using a microplate reader with cor-
rection at 540 nm. The concentration of secreted VEGF
was calculated using the standard curve created by plot-
ting the mean absorbance on y-axis against the concen-
tration on the x-axis.
RT-PCR analysis
The expression of HIF-1α and PHD2/3 were determined
by quantitative real time PCR (pRT-PCR) analysis as per
the methods described earlier [30] Total RNA was isolated
from ccRCC cells and primary tumor tissues with matched
adjacent normal kidney using the TRIzol method(Invitrogen, Carlsbad, CA). Complementary DNA (cDNA)
was synthesized from total RNA using a Superscript First-
strand synthesis kit according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). For quantitative
analysis of expression of HIF-1α and PHD2/3, qRT-PCR
was performed with SYBR green quantitative PCR tech-
nique using the Applied Biosystems Real-Time Cycler
HT-7900. Expression levels were normalized to β-actin
mRNA levels by calculating delta cycle thresholds (ΔCt)
(ΔCt=Ct of the gene (HIF-1α, PHD2/3) – Ct of β-actin).
Relative mRNA expression for each gene was normalized
to control normal kidney tissues by using 2delta-delta CT
method as described by manufacturer (Applied Biosys-
tems). For determining the expression of genes in ccRCC
cells the average delta CT values normalized to endogen-
ous β-actin control were used to show the expression
levels of genes in each cell line. Experiments were per-
formed with replicate samples.
Nude mice
Female athymic NUDE-Foxn1 (nu/nu) mice, 8–12 weeks
old (weight 20-25 g) were purchased from Harlan Sprague-
Dawley Inc., (Indianapolis, IN). Mice were kept five per
cage with water and food ad libitum according to the proto-
cols approved by the Institute Animal Care and Use Com-
mittee (IACUC) at Roswell Park Cancer Institute.
Tumor measurement and antitumor activity
Vernier Caliper was used to measure the two axis (mm)
of tumor (L, longest axis; W, shortest axis). The weight
of the tumor was estimated using the formula: tumor
weight =½ (L x W2). Tumor measurements were taken
daily for the first 8 days and at least 3 times each week
for the following 2 weeks. Antitumor activity of selenium
was determined by assessing the tumor size. Animals
were sacrificed when the tumor weight reached ~2
grams according to the Institute’s approved animal
protocols.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
Software Inc. (La Jolla, CA). Standard Student’s t-test
was used to determine the significance between un-
treated control and selenium treatments and p< 0.05
was considered as significant. To determine whether the
incidence of PHD2/3, HIF-α and VEGF in ccRCC is sig-
nificantly different from head & neck and colon cancer,
the data was analyzed by Dr. Austin Miller (Senior Bio-
statistician, Department of Biostatistics, at Roswell Park
Cancer Institute). Estimates and 95 percent confidence
limits for the proportion of tissue sample with positive
expression were calculated using Wilson Point Estima-
tion methods [31]. Statistical significance for the differ-
ence in expression was assessed using Fishers Exact test.
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null hypothesis of no difference in expression in a given
marker between the disease groups (compared to
ccRCC).
Results
Low incidence of PHD2 and VEGF-A, undetectable PHD3,
and high incidence of HIF-α, in human ccRCC tumors
compared to head & neck and colon cancers
To determine the potential clinical relevance of the ex-
pression of PHD 2/3, HIF-α and VEGF-A proteins and
their modulation by therapeutic doses of MSC, we have
evaluated their incidence, intensity and cellular distribu-
tion in ccRCC (n = 88), head & neck (n = 210), and colo-
rectal (n = 65) human primary cancer specimens. Cancer
specimens arranged in TMA were utilized to evaluate
the markers simultaneously in the same cells by double
immunohistochemical methods for HIF-α and PHD2 or
PHD3 as described earlier [27]. As shown in Figure 1A
and 1B, specific nuclear staining of HIF-1α and HIF-2α
(arrows, brown) and cytoplasmic PHD2 (middle panel,
pink) were found in ccRCC samples. PHD3 protein was
undetectable (lower panel) in all 88 tumors. The percent
incidence of these markers presented in Figure 1C shows
35% PHD2, no detectable PHD3, 92% of HIF-α (HIF-1α
and/or HIF-2α), and 56% of VEGF-A in 88 cases of
ccRCC. Some of the HIF-1α positive tumors were also
positive for HIF-2α and vice versa for HIF-2α expressing
tumor. Tumors positive for HIF-2α were excluded to de-
termine exclusively HIF-1α incidence and vice versa for
HIF-2α incidence. The data presented in Figure 1D show
that the incidence of HIF-1α only (9%) was significantly
low compared to HIF-2α only (47%) and co-expression
of HIF-1α and HIF-2α (32%) in ccRCC. In most cases,
the nuclear staining intensity was strong for both HIF-
1α and HIF-2α. Cytoplasmic staining was weak for
PHD2 and VEGF-A. The data in Figure 1A-D demon-
strated that the overall incidence and protein expression
of HIF-2α were dominant compared to HIF-1α in
ccRCC tumors.
HIF-1α staining intensity was strong in all samples of
ccRCC, and the average distribution was 66% (in 13 cases
even all tumor cells nuclei expressed HIF-1α) but the inci-
dence (presence) of HIF-1α alone was 9%. This 9% was
significantly lower than HIF-2α alone (47%). In head &
neck and colorectal cancers HIF-1α staining was less in-
tense (weak to moderate intensity) and involved in smaller
areas. HIF-2α distribution in ccRCC, head & neck, and
colorectal cancer are 15%, 5%, and 11% respectively,
meaning relatively few tumor cells express HIF-2α in posi-
tive cases. Incidence of HIF-2α only in ccRCC is relatively
high (46%) but in these positive samples, generally few
tumor cell nuclei (15%) express HIF-2α. The average dis-
tribution of PHD2 in ccRCC was 64% with weak intensity,while in head & neck and colorectal cancers PHD2 was
expressed very uniformly, almost in all tumor cells (98%
and 95% average distribution) with variable staining inten-
sity (from weak to strong). PHD3 was not detectable in
any sample of ccRCC. In contrast to ccRCC, in head &
neck and colorectal cancers, the majority of tumor cells
(84% and 78% respectively) express PHD3 from weak to
moderate intensity.
Head & neck and colon cancers have significantly high
incidence of PHD2 (86% in head & neck, and 83% in
colon) and PHD3 (21% in head & neck, and 50% in
colon), and low incidence of HIF-α (38% in head & neck,
and 27% in colon) (Figure 1C) compared to ccRCC. Des-
pite the low incidence of HIF-α, the incidence of VEGF-
A was found to be 79% and 97% in head & neck and
colon tumors, respectively (Figure 1C). Determination of
HIF-1α only, HIF-2α only, and co-expression of HIF-1α
& HIF-2α revealed that the incidence of HIF-1α only
was high (20%) in head & neck cancer compared to
colon (11%) and ccRCC (9%), whereas HIF-2α only inci-
dence was low in head & neck (17%) and colon (16%)
cancers compared to ccRCC (47%). The co-expression
incidence of HIF-1α and HIF-2α was very low in head &
neck (2%) and colon (3%) cancers compared to ccRCC
(32%) (Figure 1D). Collectively, these data suggest that
an inverse relationship trend between HIF-α incidence
and PHDs expression in ccRCC, head & neck and colon
cancers. Furthermore, the findings also revealed high in-
cidence of HIF-2α and co-expression of HIF-1α and
HIF-2α in ccRCC compared to head & neck and colon
cancers. The data presented in Table 1 is a tabulation of
the incidence ratio of HIF-1α, HIF-2α to PHD2 and
PHD3. The data indicate that the ratios of HIF-α to
PHD2 in ccRCC were approximately 5–17 fold higher
than that of head & neck and colon tumors.
CCRCC cell lines express similar HIF-α and PHDs profiles
as in clinical samples
Since PHD3 protein was undetectable in 88 ccRCC
tumors (Figure 1A and C), we have investigated the ex-
pression of PHD 2/3 mRNA and protein in selected clin-
ical samples and ccRCC cell lines. The data in Figure 2A
show the expression of PHD2, 3 and HIF-1α mRNA in
primary tumors. Quantitative real time RT-PCR (qRT-
PCR) analysis revealed the normal expression of HIF-1α,
PHD2 and significantly high expression of PHD3 mRNA
(3 out of 4) in primary tumors compared to their
matched normal kidney (Figure 2A). There was variabil-
ity in the expression of these markers among the
tumors. In accordance with the clinical samples, the
ccRCC cell lines RC2 and 786–0 expresses mRNA of
HIF-1α and PHD2/3 (Figure 2B). Like in primary tumor
tissues there was a difference in the expression levels of
these genes in the two cells lines. However, PHD3
Figure 1 Incidence of PHD2/3, HIF-α, and VEGF-A in ccRCC, head & neck and colon primary cancers. (A) Double immunohistochemical
detection of HIF-1α and PHD2/3 in TMAs of ccRCC. Representative photomicrographs (all magnification x400) of HIF-1α positive and HIF-1α
negative tumors (upper panel) showing nuclear staining of HIF-1α. Arrow indicates brown nuclear staining. Representative photomicrographs of
PHD2 positive and PHD3 negative tumors (pink cytoplasmic staining, middle panel) and PHD2/3 negative tumors showing no cytoplasmic pink
staining (lower panel). Numbers shown in the boxes are the positive/negative tumors. (B) Representative photomicrograph (x400) of HIF-2α
positive tumors in TMA of ccRCC. Arrows indicate brown nuclear staining. (C) Percent incidence of PHD2, PHD3, HIF-α (HIF-1α and/or HIF-2α), and
VEGF-A in ccRCC, head & neck, and colon primary tumor biopsies arranged in TMA. Numbers at the top of column indicate the number of
positive cases among all evaluable cases. (D) Incidence of exclusively HIF-1α, HIF-2α and both HIF-1α and HIF-2α positive cases from the primary
cancers in TMA. Some of the HIF-1α positive tumors turned out to be positive for HIF-2α and vice versa for HIF-2α positive tumors, which were
excluded to count only HIF-1α, HIF-2α, and both HIF-1α and HIF-2α positive cases. The co-expression of HIF-1α and HIF-2α together was also
significantly higher in ccRCC as compared to head & neck and colon cancers. Fisher Exact test revealed the statistically significant difference of
incidence in ccRCC when compared to head & neck and colon cancers.*P< 0.001.
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http://www.biomedcentral.com/1471-2407/12/293protein was undetectable in 88 tumor tissues by immu-
nohistochemistry (Figure 1C) and in two cell lines
(Figure 2D). A very weak expression of PHD3 was found
by western blot analysis in tumor tissues (Figure 2C),
likely derived from stromal cells since the whole tumor
extract was used to do western blot analysis. The ccRCC
cells RC2 and 786–0 used to determine mechanism of
HIF-1α regulation by PHDs have similar molecular pro-
file like clinical samples expressing PHD2 protein and
deficient in PHD3 protein but not mRNA (Figure 2B
and D).
Inhibition of HIF-1α and HIF-2α by MSA does not
translate into comparable downregulation of secreted
VEGF, but inhibit the growth of cells
The data presented in Figure 3 demonstrated that treat-
ment with a pharmacological dose of MSA (10 μM) the
active metabolite of MSC, resulted in the inhibition of
constitutively expressed HIF-1α and HIF-2α in RC2 and786–0 cells, respectively (Figure 3A). The observed ef-
fective inhibition of HIF-α was associated with signifi-
cant downregulation of secreted VEGF in RC2 cells
expressing HIF-1α but not in 786–0 cells expressing
HIF-2α (Figure 3B). The data in Figure 3B also indicate
that HIF-2α expressing 786–0 cells secreted significantly
less VEGF than HIF-1α expressing RC2 cells which
might explain the lack of down-regulation of secreted
VEGF by MSA. However, under hypoxic conditions,
when the secreted VEGF was higher than normoxic con-
ditions, MSA decreased the secreted VEGF levels (data
not shown). Irrespective of VEGF levels, inhibition of
HIF-α by MSA was associated with significant growth
inhibition of RC2 and 786–0 cells (Figure 3C). The
results in RC2 cells expressing HIF-1α are consistent
with our previous findings of HIF-1α inhibition by MSA
resulted in the downregulation of VEGF and growth in-
hibition in head & neck tumors [22]. The data in
Figure 3D shows the VHL restoration degraded HIF-1α
Figure 2 Expression of HIF-α, PHD2, and PHD3 mRNA and protein in ccRCC clinical specimens and cell lines. (A) Quantitative analysis of
HIF-1α, PHD2, and PHD3 mRNA by real-time RT-PCR (qRT-PCR) in ccRCC primary tumors. Expressions were normalized to the matched normal
kidney tissue by calculating 2delta-deltaCT values relative to normal kidney reference. Expression of mRNA in individual tumors was shown. B.
Expression analysis of HIF-1α, PHD2, and PHD3 in ccRCC cells RC2 and 786–0. Expression was normalized to endogenous β-actin by calculating
delta cycle threshold (ΔCt). ΔCt = Ct value of specific gene (HIF-1α, PHD2 and PHD3) - Ct value of β-actin. The lower the ΔCt value the higher the
expression of the gene. Experiment was repeated twice with triplicates and p< 0.05 was considered as significant P< 0.001. (C) Detection of
HIF-1α, HIF-2α and PHD2/3 in ccRCC primary tumors and their matched normal kidney tissues by western blot analysis. 80 micrograms of protein
extract was electrophoresed through Mini-Protean precast 4-20% gradient gel. Expression of β-actin was used as a loading control. (D) PHD3
protein was undetectable in ccRCC cells. Detection of HIF-α and PHD2/3 by western blot analysis in ccRCC cells RC2 and 786–0 cells. β-actin
expression was used as a loading control.
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http://www.biomedcentral.com/1471-2407/12/293in RC2VHL cells but did not alter the sensitivity for
MSA under aerobic culture conditions.
MSA inhibits HIF-1α through post-translational
degradation
Three approaches were used to determine whether in-
hibition of HIF-1α by MSA is at transcriptional or post-
translational modification: I) Time dependent inhibition
of HIF-1α protein synthesis by MSA was compared to a
known protein synthesis inhibitor, cycloheximide (CHX);
II) Determine MSA effect on incorporation of 35 S-Me-
thionine in protein synthesis, III) Evaluate the effect of a
proteasome inhibitor, MG132 alone and in combinationTable 1 Ratio of HIF-α to PHDs incidence in solid tumor
specimens
Incidence ratio@
HIF-1α/PHD2 HIF-1α/PHD3 HIF-2α/PHD2 HIF-2α/PHD3
ccRCC 1.29* - 2.22* -
H & N 0.22 1.25 0.13 0.72
Colorectal 0.15 0.26 0.18 0.32
@Incidence ratio was calculated by dividing incidence of HIF-α by the
incidence of PHD2 or PHD3. *P< 0.01.with MSA on HIF-1α degradation. The results presented
in Figure 4A show that HIF-1α protein synthesis was
inhibited by CHX but not by MSA alone in FaDu cells
indicating that HIF-1α protein synthesis was not affected
by MSA. In RC2 cells CHX inhibited protein synthesis
at 4 h (data not shown) and 8 h (Figure 4B). There was
some inhibition of HIF-1α with MSA alone at 8 h treat-
ment point which may be due to degradation
(Figure 4B). To evaluate precisely whether MSA is inhibit-
ing protein synthesis we have investigated the radiolabeled
amino acid incorporation studies with 35 S-Methionine,
and compared with known protein synthesis inhibitor
CHX. The results presented in Figure 4C and D clearly
shows that MSA did not inhibit the protein synthesis at
5 h time point in RC2 cells. These results suggest that
MSA may inhibit HIF-1α through degradation pathway.
To determine whether the selenium mediated degrad-
ation of HIF-1α was proteasome dependent, FaDu and
RC2 cells were treated with proteasome inhibitor
MG132 alone and in combination with MSA and results
are shown in Figure 4E and F. The results indicate that
while MSA treatment resulted in significant inhibition of
HIF-1α, the inhibition of proteasome by MG132 resulted
Figure 3 Effect of selenium treatment on HIF-1α, HIF-2α, VEGF and cell growth. (A) MSA inhibits both HIF-1α and HIF-2α. RC2 cells
expressing HIF-1α and 786–0 cells expressing HIF-2α were treated with and without 10 μM MSA for 24 h; HIF-1α and HIF-2α were detected by
western blot. β-actin expression was used as a loading control. (B) MSA down-regulates secreted VEGF in RC2 cells but not in 786–0 cells.
Secreted VEGF was measured by ELISA in ccRCC cells. Cells were treated with and without MSA for 24 h and media were used to measure VEGF
in RC2 and 786–0 cells and normalized with protein and expressed as pg/mg protein. Experiment was repeated twice with duplicates and P
value< 0.05 was considered as significant. (C). HIF-α inhibition by MSA was associated with growth inhibition. Cells were treated with various
concentrations MSA (3, 5, 7 and 10 μM) for 24 h. Medium was removed, rinsed and fresh medium was added and allowed to proliferate for 96 h.
Cells were fixed and determined the cell survival by SRB assay. Growth inhibition was presented as percent growth inhibition compared to
untreated controls. Experiment was repeated twice with 4–5 replicate samples. *p <0.001. (D). VHL transfected RC2 cells which do not express
HIF-1α were equally sensitive to MSA like RC2 cells which express HIF-1α . Expression of HIF-1α in RC2 and VHL transfected RC2 VHL cells with
and without MSA (upper panel). Cytotoxic effects of MSA in RC2 and RC2 VHL cells (lower panel). Cell survival was determined by SRB assay.
*p <0.001.
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http://www.biomedcentral.com/1471-2407/12/293in accumulation of HIF-1α, and this accumulated HIF-1α
was not removed by MSA in FaDu cells. In contrast, MSA
treatment resulted in degradation of HIF-1α independ-
ent of proteasome inhibitor MG132 in RC2 cells. These
data suggest that degradation of HIF-1α by MSA was
proteasome dependent in FaDu cells but not in RC2
cells.
Degradation of HIF-1α by MSA is PHD2 dependent and
VHL independent
VHL is inactivated in several human ccRCC [1] and
PHD3 is undetectable in all of the 88 ccRCC specimens
tested (Figure 1C) and ccRCC cell lines (Figure 2D). To
test the hypothesis that the degradation of HIF-1α by
MSA is PHD2 dependent, and VHL independent, two
approaches were evaluated: i) treat with PHD2 activity
inhibitor, DMOG alone and in combination with MSA
(Figure 5A) and ii) treat with siRNA against PHD2
(Figure 5B) and VHL (Figure 5C) with the combination
of MSA. Since RC2 and 786–0 cells express mutated
VHL, we have used FaDu cells which express wild type
VHL. HIF-1α is not detectable in FaDu cells under nor-
moxic culture conditions expressing PHD2 and PHD3[22]. However, inhibition of PHDs activity by DMOG
resulted in stable expression of HIF-1α. Treatment of
MSA in combination with DMOG did not result in deg-
radation of HIF-1α in FaDu cells expressing PHD2/3
(Figure 5A). In support of these findings, MSA treat-
ment leads to degradation of HIF-1α in RC2 cells
expressing PHD2 protein with nonfunctional VHL and
this degradation is reversed in combination with DMOG
(Figure 5A). Consistent with these findings, inhibition of
PHD2 by siRNA did not resulted in the degradation of
HIF-1α by MSA in RC2 tumor cells expressing constitu-
tive HIF-1α with mutated VHL (Figure 5B). The data in
Figure 5C demonstrated that inhibition of VHL by
siRNA did not prevent HIF-1α degradation by MSA in
FaDu cells expressing functional VHL. Collectively, the
data is consistent with the hypothesis that degradation
of HIF-1α by a pharmacological dose of MSA is PHD2
dependent, and VHL independent.
Degradation of HIF-2α by MSC is associated with
antitumor activity in 786–0 tumor xenografts
To confirm that inhibition of HIF-2α by a nontoxic dose
of MSC will translate into therapeutic benefits, 786–0
Figure 4 Effect of MSA on HIF-1α protein synthesis and degradation. (A) HIF-1α synthesis was inhibited by cycloheximide but not by MSA
in FaDu cells. FaDu cells were treated with 1 μM MSA and 10 μM cycloheximide alone and in combination for 1.5, 2, 3 and 24 hours at 0.5%
oxygen and protein extracts were used to determine HIF-1α by western blot. β-actin expression was used as a loading control. (B) Effect of MSA
on HIF-1α protein synthesis in RC2 cells. Cells were treated with cycloheximide or MSA alone and in combination for 8 h. HIF-1α was detected by
western blot. β-actin was used as loading control (C) Incorporation of 35 S-Methionine was not affected by MSA in RC2. Cells were treated with
cycloheximide or MSA separately in duplicate samples for 5 h and 35 S-Methionine (2.3 μCi/ml) was added at the last 1 h of treatment. Protein
extracts (20 μg) were used to separate by SDS polyacrylamide gel electrophoresis and detected the incorporated 35 S-Methionin by
autoradiography. Lower panel showing the coomassie blue stained proteins as loading control. (D) Determination of 35 S-Methionine radioactivity
counts in cycloheximide or MSA treated RC2 cells. Protein extracts (20 μl) were used to detect 35 S-methionine radioactivity in the cells by
counting in Liquid Scientilator Counter. Total counts were calculated in one milligram of protein and presented the number of counts in millions
as compared to untreated control cells. P< 0.05 was considered as significant. (E) HIF-1α degradation by MSA is proteasome dependent. FaDu
cells which do not express constitutive HIF-1α under normoxic culture conditions were subjected to 0.5% oxygen and treated with 1 μM MSA
alone and in combination with 10 μM proteasome inhibitor MG132 for 24 h. Cell extracts were prepared and the expression of HIF-l α was
analyzed. Expression of β-actin was used as a loading control. (F) Proteasome independent degradation of HIF-1α in VHL mutated RC2 cells. RC2
cells were treated with MSA and MG132 alone and in combination for 8 h. In a separate experiment, 1 h pre-treatment of MG132 followed by
7 h MSA treatment was performed to see the effect of MSA on HIF-1α. Cells were processed to extract protein and HIF-1α levels were
determined. Expression of β-actin was used as a loading control.
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http://www.biomedcentral.com/1471-2407/12/293xenografts expressing constitutively active HIF-2α were
treated orally daily with 0.2 mg/mouse/day MSC for
18 days. The data presented in Figure 6 showed that MSC
treatment resulted in significant inhibition of tumor
growth (Figure 6A) which was associated with inhibition
of HIF-2α (Figure 6B). These data are consistent with the
previous finding from this laboratory demonstrating thatthe inhibition of HIF-1α by MSC resulted in significant
antitumor activity against FaDu tumor xenografts [22].
Discussion
The expression of PHD2/3, the main regulators of HIF-α
has not been investigated in primary human ccRCC
using double immunohistochemical staining to detect
Figure 5 Role of PHDs in HIF-1α degradation by MSA. (A) Inhibition of PHDs activity by DMOG reversed the degradation of HIF-1α by MSA in
VHL active FaDu, and VHL inactive RC2 cells. Cells were treated with 10 μM MSA and 0.5 mM DMOG alone and in combination and HIF-1α was
analyzed by western blot. β-actin expression was used as a loading control. (B) Gene specific silencing of PHD2 in RC2 cells by siRNA prevented
the degradation of HIF-1α by MSA. PHD2 siRNA was transfected with lipofectamine 2000 for 24 h. Cells were treated with and without 10 μM
MSA for 24 h and HIF-1α was detected by western blot. β-actin expression was used as a loading control. (C) Degradation of HIF-1α by MSA is
VHL independent. VHL was inhibited by siRNA in FaDu cells expressing active VHL and treated with MSA to determine the HIF-1α degradation.
This experiment was done under 0.5% oxygen level to stabilize HIF-1α in FaDu cells. β-actin expression was used as a loading control.
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http://www.biomedcentral.com/1471-2407/12/293these proteins simultaneously in consecutive sections of
the same tumors. In this study, we have demonstrated
low incidence, distribution and staining intensity of
PHD2, deficient PHD3 protein, and high HIF-α inci-
dence, distribution and intensity in 88 primary ccRCC
cancers compared to head & neck and colorectal cancers
(Figure 1A, B and C). Furthermore, like clinical samples,
the two ccRCC cell lines (RC2 and 786–0) used for
mechanistic studies were deficient in PHD3 protein
(Figure 2D) but not mRNA (Figure 2B). The highFigure 6 MSC effect on tumor growth and HIF-2α expression in 786–
xenografts. HIF-2α expressing 786–0 cells (10 million) were transplanted int
tumor tissues were transplanted subcutaneously into nude mice and treatm
randomized and divided into two groups, each containing 5 mice. One gro
(0.2 mg/mouse/day; the optimal nontoxic dose) daily for 18 days. Tumor vo
dose of MSC in 786–0 xenografts. Tumor xenografts collected after 18 days
levels were assessed by western blot. β-actin expression was used as a loadincidence of HIF-α in ccRCC has been partially linked to
the mutation of VHL gene. The VHL gene mutation inci-
dence varies from 19.6 to 89.4% in ccRCC [32,33] and the
majority of reports show 30-60% mutation incidence [34].
Furthermore, the up-regulation of both HIF-1α (88.2%)
and HIF-2α (100%) with only 39.1% VHL mutations was
found in ccRCC showing the VHL independent up-
regulation of HIF-α in many cases [34]. Our results sug-
gest a role for PHD2/3 in addition to the well documented
VHL mutations in the constitutive expression of HIF-α in0 ccRCC xenografts. (A) Inhibition of ccRCC tumor growth by MSC in
o nude mice for establishing the xenografts. Small pieces (~50 mg) of
ent began when tumor weighed 200–250 mg. Mice were
up was treated with saline and the other group was treated with MSC
lume was measured daily. (B) HIF-2α is inhibited by the therapeutic
of the MSC treatments and processed to extract protein and HIF-2α
ing control.
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http://www.biomedcentral.com/1471-2407/12/293ccRCC. A recent report showed the silencing of PHD3 ex-
pression by CpG methylation in the promoter region of
human cancer cell lines including renal cancer, prostate,
breast and melanoma [12], and in plasma cells and B-cell
lymphoma, suggesting PHD3 as a potential biomarker
[35]. In addition, Astuli et al., [36] found the absence of
pathogenic mutations in PHD1, 2 and 3 that could cause
renal cell carcinoma. Our western blot analysis showed
very weak expression of PHD3 protein compared to
PHD2 (Figure 2C) in two representative primary tumor
cases. This weak signal may be derived from the normal
stromal cells expressing PHD3 [9]. These results suggest
that there may be some epigenetic regulation of PHD3 ex-
pression in ccRCC that might lead to the degradation or
inhibition of PHD3 protein. A recent clinical study
showed a positive correlation between decreased PHD3
expression and aggressive type of breast tumors [37].
Similarly, the lack of expression or low incidence/intensity
of PHD3 may contribute to the aggressiveness of ccRCC
tumors. Thus, the agents that enhance HIF-α degradation
by PHD2, independent of PHD3 expression may offer
treatment modality that could affect resistance and clinical
outcome.
This laboratory is the first to show that therapeutic
dose of selenium as highly effective inhibitor of both
constitutively expressed HIF-1α, HIF-2α in ccRCC
(Figure 3A and 6B) and hypoxia induced HIF-1α in head
& neck cancer [22]. Consistent with our data, published
results show the degradation of constitutively expressed
HIF-1α in prostate cancer [38] and hypoxia induced
HIF-1α in B-cell lymphoma [39] by selenium. These
findings show that both hypoxia induced and constitu-
tively expressed HIF-α are inhibited by selenium sug-
gesting that selenium could inhibit growth of tumors
expressing HIF-1α, HIF-2α or both. HIF-α transcription-
ally regulated gene, VEGF, is regulated by MSA in renal
cancer cells (Figure 3B). MSA treatment leads to the
down-regulation of secreted VEGF in HIF-1α expressing
RC2. The lack of MSA effects on secreted VEGF in
786–0 cells could be due to low levels of secreted VEGF
in these cells. To our surprise we did not see difference
in cytotoxic effects of MSA in RC2 and RC2VHL cells
even though there is a marked difference in HIF-1α
levels in these cells under normoxic culture conditions.
This may be due to the other effects of MSA in these
particular cells with VHL transfection. VHL being a
multifunctional adaptor molecule involved in the inhib-
ition of HIF-α independent and dependent cellular pro-
cesses [40]. The cytotoxic effects of MSA in RC2VHL
cells may be through VHL interacting proteins. Our data
demonstrate that selenium main target HIF-α is
degraded by PHD dependent and VHL independent, but
some of our unexpected findings with VHL transfected
RC2 cells indicate that VHL transfection may influencethe cytotoxic effects of MSA independent of HIF-1α by
currently unclear molecular mechanism.
We have demonstrated HIF-α inhibition by selenium
as a post-translational degradation mechanism. As
shown in the Figure 4A and B, MSA did not affect HIF-
α protein synthesis. In a separate experiment, we have
demonstrated that the overall protein synthesis was not
altered by MSA using the 35 S-Methionine incorporation
studies (Figure 4C and D). The proteasome inhibitor
MG132 reversed the degradation of HIF-α by MSA in
FaDu cells (Figure 4E) demonstrating the proteasome
dependent degradation. In contrast, in RC2 cells prote-
asome inhibition did not reverse the degradation of HIF-1α
by MSA suggest that in VHL mutant cells MSA may be de-
grading HIF-1α through proteasome independent pathway.
Further detailed mechanistic studies need to be performed
to investigate how MSA is degrading HIF-α in the absence
of VHL in ccRCC. Our results also show that MSA is un-
able to degrade HIF-1α stabilized by DMOG, an inhibitor
of PHDs activity (Figure 5A). DMOG inhibits PHD activity
by competing with 2-oxoglutarate, a cofactor for PHDs ac-
tivity. In addition, gene specific inhibition of PHD2 also
prevented the degradation of HIF-1α by MSA (Figure 5B).
Furthermore, we have confirmed VHL independent deg-
radation of HIF-1α by silencing of VHL with siRNA in
VHL positive FaDu cells (Figure 5C). As reported in the lit-
erature, VHL knockdown did not lead an increase of HIF-
1α in FaDu cells under hypoxic conditions [41]. These
results indicate that selenium utilizes a unique pathway for
HIF-1α degradation through PHD2 dependent and VHL
independent degradation mechanism. Future studies
are warranted to investigate specific function of
PHD2 that might be altered by selenium leading to
the degradation of HIF-α through another ligase in-
dependent of VHL.
Our recent report [22] and study by Sinha et al., [38]
demonstrated stabilization of PHDs by MSA leads to the
degradation of HIF-1α. HIF-1α degradation through
VHL dependent and independent pathways is known.
Under aerobic conditions, HIF-1α is hydroxylated at 402
and 564 proline molecules by PHDs and recognized by
VHL and further degraded by proteasome [42,43]. HIF-
1α is also degraded without PHD through a small
ubiquitin-like modifier (SUMO)ylation that allows the
binding of VHL to further degrade HIF-1α by prote-
asome [44]. There has been growing evidence for VHL
independent degradation of HIF-1α through histone
deacetylases (HDACs) inhibition [28,39], heat shock pro-
tein 90 (HSP90) [45,46], the hypoxia associated factor
(HAF) [47] and an undescribed cullin-independent pro-
teasome degradation pathway [29,48].
Based on the demonstrated low incidence of PHD2,
lack of PHD3 protein and high incidence of HIF-α in
ccRCC, we expect that HIF-α mediated drug resistance
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http://www.biomedcentral.com/1471-2407/12/293is particularly important in this type of cancer. There-
fore, decreasing HIF-α expression in ccRCC cells seems
to be an important new strategy in order to sensitize
tumor cells to the currently used standard therapy. We
found MSA treatment lead to 786–0 tumor growth in-
hibition which correlated with reduced HIF-2α protein
levels (Figure 6). It is important to indicate that although
HIF-1α role in drug resistance has been widely evaluated
[49], to date, efforts have been focused on the develop-
ment of agents that would effectively inhibit HIF-1α syn-
thesis [50-52]. MSC represents a new type of HIF-α
inhibitor by enhancing the degradation, but not affecting
the synthesis of HIF-α. Currently, it is difficult to predict
what approach of HIF-α inhibition combined with
chemotherapy will improve the cancer therapy. Further-
more, utilization of clinically more relevant orthotopic
imageable mouse models [53-55] would be more appro-
priate for further development of MSC as HIF-α inhibi-
tor in ccRCC.
Conclusions
We have demonstrated that low incidence of PHD2 and
deficiency of PHD3 protein associated with high incidence
of HIF-α in ccRCC. Both HIF-1α and HIF-2α are inhibited
by MSC through PHD2 dependent and VHL independent
degradation mechanism. Furthermore, HIF-2α degrad-
ation by MSC leads to inhibition of the growth of ccRCC
tumor xenografts without toxicity. Thus, our data sup-
ports further evaluation of MSC as a HIF-α inhibitor in
combination with multikinase inhibitors, like sunitinib, to
determine their efficacy in ccRCC xenograft model.
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